ABSTRACT
investigating the quantitative analysis of FDG-PET/CT at staging. In this regard the measurement of the Total metabolic tumor volume (TMTV), which gives an estimation of the total tumor burden, has gained special interest. Indeed several series have shown that TMTV was predictive of outcome in different lymphoma subtypes, Diffuse Large B cell lymphoma (DLBCL) (2,3), Hodgkin lymphoma (HL) (4), Peripheral T cell lymphoma (PTCL) (5) and Follicular lymphoma (FL) (6) . In these studies, different methods of TMTV measurement were used; all were based on a fixed thresholding principle to determine the metabolic volume of local tumors. The threshold can be absolute: a SUV value of 2.5 was generally chosen (2) . It can be relative, using a percentage of the maximum uptake. A threshold of 41% of the SUVmax within the lesion, recommended by the European Association of Nuclear Medicine (EANM) for solid tumor (7) has been used in patients with HL (4), DLBCL (3) and PTCL (5) with a good inter observer reproducibility. However, since lymphomas are heterogeneous disease with several tumor sites with a wide range of volumes, SUV and tumor background ratios, the adaptive segmentation methods might be of interest for TMTV measurement and could be proposed as an alternative to fixed thresholding methods. The principle of these adaptive methods developed for radiotherapy planning of solid tumors is to adapt the threshold following a fitting model according to one or two characteristic image parameters, such as the SUV or the contrast. In a previous study we have demonstrated in a retrospective group of PTCL patients that TMTV measured with the 41%SUVmax threshold method was a good predictor of outcome (5) . The aim of the present study was to compare in the same series, taken as a model of diffuse lymphoma, different adaptive thresholding methods to this fixed 41% method and to evaluate if they were better predictors of outcome than a fixed relative threshold. Committee with a waiver of informed consent due to its retrospective nature (5).
MATERIALS AND METHODS

Patients
PET acquisition
All the centers adhered to EANM guidelines for patient preparation and PET/CT acquisition. All patients were instructed to fast for at least 6 hours before the injection of 4-5 MBq per kilogram of 18F FDG, to ensure that serum glucose and endogenous serum insulin levels were low. Non contrast enhanced CT images were acquired before PET data acquisition. Whole body PET was acquired sequentially using a dedicated PET/CT system. For the PET imaging, the emission data were acquired from the base of the skull to the proximal thigh with 3 to 3.5 min of acquisition per bed position. Biograph Sensation 16 Hi-Rez (Siemens Medical Solution, Knoxville, TN, USA) or Gemini GXL or Gemini TOF (Philips, Da Best, The Netherlands) were used by the 5 centers. All the devices used in this study followed a QC program insuring that the data were quantitatively correct (quarterly SUV verification). Four centers had obtained EARL accreditation at the time of the study and one was accredited according to RTEP procedure (8) . The similarity of performances of the different equipment was confirmed with the analysis of the recovery curves obtained from their NEMA phantoms in terms of volume and contrast.
TMTV measurement
The baseline FDG PET/CT was processed with a Planet Onco workstation (Planet Onco v2.0, DOSISoft, Cachan, France) localized in Henri Becquerel Center, Rouen.
TMTV was computed following these steps:
First, the volumetric regions of interest (VOI) were placed around each lesion, avoiding physiological uptake (urinary elimination, heart). The reproducibility of the ROI setting has been evaluated, as previously published (5) . Then the tumor volume was delineated with 5 thresholding methods: one fixed, 41% SUVmax considered thereafter as the reference (9) and 4 adaptive based on mathematical algorithms: Daisne modified by Vauclin et al (TMTVDa) which iteratively adapt the threshold according to the local signal to background ratio (10), Fitting (TMTVFit) which fit the sphere image using a 3D geometric model based on the spatial resolution in the reconstructed images and on a tumor shape derived from activity thresholding (11,12), Nestle (TMTVNs) according to tumor and background intensities (13) , and Black (TMTVBl) according to the SUVmean (14) . The tumor SUVmax and the liver SUVmax were also reported.
Statistical analysis:
Quantitative variables were expressed as median and ranges. Comparison of TMTV between methods was analyzed with the Friedman non-parametric test. When a significant difference was detected, Wilcoxon signed-rank test was performed, with Bonferroni correction for multiple testing. Correlation between TMTV values from the 41% SUVmax method and those from adaptive methods (Daisne modified, Fitting, Nestle and Black) was tested using Spearman coefficients. Agreement between methods were represented on the Bland Altman plots and quantified with the intra-class correlation coefficient (ICC) based on Shrout-Fleiss formulae.
For each method Receiver Operating Curve (ROC) were obtained to define the optimal TMTV cutoff for survival prediction. The prognostic relevance of each method to predict PFS and OS was pairwise comparison of these ROC curves. Survival functions were calculated using KaplanMeier (KM) estimates for each method using their optimal TMTV cutoff. Comparison between categories was made using the log-rank test and Cox proportional-hazards models. The agreement between the dichotomization of patients in low and high TMTV group obtained with the 41% SUVmax method and each adaptive method was tested with the Cohen's kappa coefficient. Survival functions were also calculated for each method by using the threshold of 230 cm
RESULTS
One-hundred and six patients with PTCL newly diagnosed and for whom PET/CT could be retrieved for analysis on Dosisoft software were included in the present study. Characteristics of this group was similar to the initial population
TMTV measurements
The median value of TMTV41%, TMTVDa, TMTVFit, TMTVNs and TMTVBl were 231 cm The Bland Altman plots are presented in Fig. 2 . Looking at TMTV under 500 cm 3 , the mean differences between 41%SUVmax and adaptive methods were really reduced: 21.8 ±36.3 for TMTVDa, 21±34.8 for TMTVFit, 0.4 ±54.5
for TMTVNs, and -105.8 ± 124.5 for TMTVBl.
The intra-class correlation coefficient (ICC) varied from 0.972 and 0.988 for TMTVDa, TMTVFit, TMTVNs and was 0.856 for TMTVBl. The coefficient of variation between TMTV41% and TMTVDa, TMTVFit, TMTVNs, TMTVBl were respectively 14%, 14%, 21% and 48%.
Prognostic value of the different methods
The respective optimal cutoff found with ROC analysis for TMTV41%, TMTVDa, TMTVFit, TMTVNs and TMTVBl were 230 cm (Fig. 3) . A significant difference was observed for TMTVBl on PFS (p=0.02). No significant difference was observed for OS.
TMTV was significantly associated with inferior PFS (p<0.001) and OS (p<0.001) whatever the method of computation, with no significant difference between them and similar hazard ratio (table 1) . The hazard ratio ranged from 3.7 (TMTVBl) to 4.1 (TMTV41%) on PFS and from 3.0 (TMTVBl) to 3.5 (TMTVDa) on OS. The 2y-PFS ranged from 66% to 72% for the low TMTV groups vs 26-29% for the high TMTV groups and 2y-OS from 79% to 83% vs 50 to 53% (Fig. 4) . 
DISCUSSION
The major result of this study is to show that the prognostic value of baseline TMTV computed with several adaptive methods was similar to TMTV computed with 41% SUVmax threshold method in a large series of PTCL patients taken as an example of diffuse tumor disease.
Retrospective studies have demonstrated that TMTV was a powerful predictor of outcome in different lymphoma subtypes. TMTV measurement at baseline is important since it could help stratifying patient in different risk categories and has been suggested as a possible tool for early guiding therapy. However until now in lymphoma different TMTV methodologies have been used: an absolute cutoff of SUV>2.5 or a relative SUVmax thresholding of the tumor sites. The absolute threshold using SUV>2.5 is limited by the variability of SUV values, due to PET/CT devices, PET acquisition protocol and reconstruction methods. In addition due to partial volume effect non tumor regions located between small distant nodes with high uptake could be included (15, 16) . Therefore relative thresholds have been used in several lymphoma studies: a 41% SUVmax cutoff as recommended by EANM guidelines for solid tumors was applied in DLBCL, HL, FL, and PTCL and a 25% SUVmax recently evaluated in PBMCL (17).
Lymphoma characteristics, i.e a disseminated disease with different size of lesion, different sites with nodal or extra nodal lesions and heterogeneous FDG uptake (tumor/liver ratios varying from one to 15 in our series), might limit the efficiency of both fixed threshold methods. Conversely, adaptive methods may be more accurate and even easier to use in routine but they had not been yet tested on lymphoma.
In a previous study we have shown in PTCL that baseline TMTV with a 230 cm 3 threshold was a good tool for outcome prediction and predicted progression free and overall survival much better than the currently used clinical index.
In the same series of patients we observed that the intra-class correlation coefficient found between TMTV values obtained with the three adaptive methods (Daisne modified, Fit and Nestle) and those from the 41% SUVmax method were excellent. The optimal threshold dichotomizing the population in low and high volumes groups for each adaptive method were different but, despite these differences, all these methods predicted PFS and OS with similar p and HR values for small and large volumes. The only slight incremental prognostic value compared to 41% threshold was observed for Daisne modified for OS prediction. Moreover when the same threshold of TMTV obtained with the 41%SUVmax method (230cm Several quantitative measurements including TMTV and TLG have been done in ancillary studies of prospective trials based on quality controlled PET (2, 6, 17) . However, to our knowledge, no ongoing trials have been launched using the TMTV to guide therapy. Even if the prerequisite for this type of trial is quality control, as done using various existing control systems (7, 19, 20) , it is anyway required for good PET clinical practice. The main problem is which TMTV technique measurement should be chosen as there is no established consensus. We think that relative methods (SUVmax thresholding or adaptive) have the advantage to minimize the errors linked to the use of different devices and the participation of different centers.
In addition our results suggest that it is possible to conduct a prospective trial based on TMTV measurement provided one single relative method of TMTV measurement is used by all participating centers. The 41% TMTV threshold method is currently available in all commercial software and can be used in the majority of the PET/CT system. It has demonstrated a good reproducibility among trained observers but requires accurate manual drawing of the VOI around each lesion. Adaptive methods might be an option if available in all the centers.
CONCLUSION
Our results demonstrate that adaptive methods can be used with the same efficacy as 41% TMTV method in PTCL and would open the way to automatic procedures of volume computation. These conclusions should be confirmed for other types of diffuse aggressive lymphoma and new generation devices.
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